Dirección de esta página: https://medlineplus.gov/spanish/druginfo/natural/307.html

Resveratrol

¿Qué es?

El resveratrol es una sustancia química que se encuentra presente en el vino tinto, la piel de la uva roja, el jugo de uva morada, las moras y en una menor cantidad en los cacahuetes. Se usa como un medicamento.

La gente usa el resveratrol para el "endurecimiento de las arterias" (arterioesclerosis), para bajar los niveles del colesterol "malo" (LDL), para aumentar los niveles del colesterol "Bueno" (HDL) y para prevenir el cáncer.

¿Qué tan efectivo es?

Natural Medicines Comprehensive Database (La Base Exhaustiva de Datos de Medicamentos Naturales) clasifica la eficacia, basada en evidencia científica, de acuerdo a la siguiente escala: Eficaz, Probablemente Eficaz, Posiblemente Eficaz, Posiblemente Ineficaz, Probablemente Ineficaz, Ineficaz, e Insuficiente Evidencia para Hacer una Determinación.

La clasificación de la eficacia para este producto es la siguiente:

Insuficiente evidencia para hacer una determinación para...

  • Acné. La evidencia preliminar muestra que la aplicación en la cara de un gel que contiene resveratrol podría disminuir la gravedad del acné.
  • Enfermedad pulmonar (enfermedad pulmonar obstructiva crónica [EPOC, COPD]). Cierta investigación preliminar sugiere que la ingesta de un producto combinado que contiene resveratrol, vitamina C, cinc y flavonoides disminuye levemente la tos y la producción de mucosidad en personas con EPOC.
  • Diabetes. Cierta investigación sugiere que la ingesta de 5 mg de resveratrol dos veces por semanas durante 4 semanas no afecta los niveles de insulina en personas con diabetes. Sin embargo, otra investigación muestra que la ingesta diaria de un producto específico que contiene resveratrol linaza (Biofort) durante tres meses disminuye los niveles de azúcar en la sangre, la presion arterial y los niveles de lípidos en la sangre.
  • "endurecimiento de las arterias" (arterioesclerosis)..
  • Colesterol alto.
  • Prevenir cáncer.
  • Otras afecciones
Se necesita más evidencia para poder aprobar al resveratrol para estos usos.

¿Cómo funciona?

El resveratrol podría expandir los vasos sanguíneos y disminuir la actividad de células importantes en la coagulación sanguínea. Algunas investigaciones sugieren que el resveratrol tiene efectos como estrógeno pero estos son débiles. Puede también disminuir el dolor y la hinchazón (inflamación).

¿Hay preocupación por la seguridad de su uso?

El resveratrol es POSIBLEMENTE SEGURO cuando se lo usa en cantidades que se encuentran en los alimentos y cuando se consume en dosis de hasta 250 mg diarios durante un máximo de tres meses. Se informó la ingesta de dosis altas de hasta 900 mg durante un máximo de dos días. Se informó la aplicación de resveratrol en condiciones de seguridad durante un máximo de 30 días.

Advertencias y precauciones especiales:

Embarazo y lactancia: El resveratrol es PROBABLEMENTE SEGURO cuando se usa en las cantidades en las que se encuentra en algunos alimentos; sin embargo, durante el embarazo y lactancia, la fuente del resveratrol es importante. El resveratrol se encuentra presente en la piel de las uvas, el jugo de uva, el vino y otras fuentes alimenticias. Durante el embarazo y la lactancia no debería consumirse vino como fuente de resveratrol.

Trastornos hemorrágicos: El resveratrol podría disminuir la coagulación de la sangre. En teoría, el resveratrol podría aumentar el riesgo hemorragia en personas con trastornos hemorrágicos.

Trastornos sensibles a las hormonas como cáncer de mamas, cáncer uterino, cáncer de los ovarios, endometriosis o fibromas uterinos: El resveratrol podría tener un efecto como estrógeno. No tome resveratrol si tiene una enfermedad que podría empeorar con la exposición al estrógeno.

Cirugía: El resveratrol podría aumentar el riesgo de sangrado durante y después de una cirugía. Deje de tomar resveratrol por lo menos 2 semanas antes de tener un procedimiento quirúrgico.

¿Existen interacciones con medicamentos?

Moderadas
Tenga cuidado con esta combinación
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 1A1 (CYP1A1))
Algunos medicamentos son alterados y descompuestos por el hígado. El resveratrol podría disminuir la velocidad con la que hígado descompone ciertos medicamentos. La ingesta de resveratrol junto con algunos medicamentos que son modificados por el hígado podría aumentar los efectos y los efectos secundarios de algunos medicamentos. Antes de la ingesta de resveratrol, consulte con su proveedor de salud si toma medicamentos que son alterados por el hígado.

Ciertos medicamentos modificados por el hígado incluyen clorzoxazona, teofilina y bufuralol.
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 1A2 (CYP1A2))
Algunos medicamentos son alterados y descompuestos por el hígado. El resveratrol podría disminuir la velocidad con la que hígado descompone ciertos medicamentos. La ingesta de resveratrol junto con algunos medicamentos que son modificados por el hígado podría aumentar los efectos y los efectos secundarios de algunos medicamentos. Antes de la ingesta de resveratrol, consulte con su proveedor de salud si toma medicamentos que son alterados por el hígado.

Algunos de los medicamentos alterados por el hígado incluyen clozapina (Clozaril), ciclobenzaprina (Flexeril), fluvoxamina (Luvox), haloperidol (Haldol), imipramina (Tofranil), mexiletina (Mexitil), olanzapina (Zyprexa), pentazocina (Talwin), propranolol (Inderal), tacrina (Cognex), zileuton (Zyflo), zolmitriptán (Zomig) y otros.
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 1B1 (CYP1B1))
Algunos medicamentos son alterados y descompuestos por el hígado. El resveratrol podría disminuir la velocidad con la que hígado descompone ciertos medicamentos. La ingesta de resveratrol junto con algunos medicamentos que son modificados por el hígado podría aumentar los efectos y los efectos secundarios de algunos medicamentos. Antes de la ingesta de resveratrol, consulte con su proveedor de salud si toma medicamentos que son alterados por el hígado.

Ciertos medicamentos modificados por el hígado incluyen clorzoxazona, teofilina y bufuralol.
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 2C19 (CYP2C19))
Algunos medicamentos son alterados y descompuestos por el hígado. El resveratrol podría disminuir la velocidad con la que hígado descompone ciertos medicamentos. La ingesta de resveratrol junto con algunos medicamentos que son modificados por el hígado podría aumentar los efectos y los efectos secundarios de algunos medicamentos. Antes de la ingesta de resveratrol, consulte con su proveedor de salud si toma medicamentos que son alterados por el hígado.

Ciertos medicamentos modificados por el hígado incluyen amitriptilina (Elavil), carisoprodol (Soma), citalopram (Celexa), diazepam (Valium), lansoprazol (Prevacid), omeprazol (Prilosec), fenitoína (Dilantin), warfarina y otros.
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 2E1 [CYP2E1])
Algunos medicamentos son alterados y descompuestos por el hígado. El resveratrol podría disminuir la velocidad con la que hígado descompone ciertos medicamentos. La ingesta de resveratrol junto con algunos medicamentos que son modificados por el hígado podría aumentar los efectos y los efectos secundarios de algunos medicamentos. Antes de la ingesta de resveratrol, consulte con su proveedor de salud si toma medicamentos que son alterados por el hígado.

Ciertos medicamentos modificados por el hígado incluyen acetaminofén, clorzoxazona (Parafon Fortea), etanol, teofilina y anestésicos tales como enfluran (Ethrane), halotano (Fluothane), isoflurane (Forane), metoxiflurano (Penthrane).
Medicamentos modificados por el hígado (Sustratos del Citocromo P450 3A4 (CYP3A4))
Algunos medicamentos son modificados y descompuestos por el hígado. El resveratrol podría disminuir la rapidez con que el hígado descompone algunos medicamentos. El tomar resveratrol junto con otros medicamentos que son alterados por el hígado puede aumentar los efectos y efectos secundarios de algunos medicamentos. Antes de tomar resveratrol hable con su proveedor de atención médica si está tomando medicamentos que son modificados por el hígado.

Algunos medicamentos transportados por el hígado incluyen bloqueadores del canal de calcio (diltiazem, nicardipina, verapamilo), agentes quimioterapéuticos (etopósido, paclitaxel, vinblastina, vincristina, vindesina), antimicóticos (ketoconazol, itraconazol), glucocorticoides, alfentanil (Alfenta), cisaprida (Propulsid), alfentanil (Sublimaze), lidocaína (Xylocaine), losartán (Cozaar), fexofenadina (Allegra), midazolam (Versed) y otros.
Medicamentos que retardan la coagulación sanguínea (Anticoagulantes / fármacos Antiplaquetarios)
El resveratrol podría retardar la coagulación sanguínea. El tomar resveratrol junto con medicamentos que también retardan la coagulación podría aumentar la posibilidad de sufrir hematomas y pérdida de sangre.

Algunos medicamentos que retardan la coagulación sanguínea incluyen aspirina, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, otros), ibuprofeno (Advil, Motrin, otros), naproxeno (Anaprox, Naprosyn, otros), dalteparina (Fragmin), enoxaparina (Lovenox), heparina, warfarina (Coumadin), y otros.

¿Existen interacciones con hierbas y suplementos?

Hierbas y suplementos que podrían retardar la coagulación sanguínea (Hierbas y suplementos anticoagulantes/antiplaquetarias)
El resveratrol podría retardar la coagulación sanguínea. En algunas personas el uso de resveratrol junto con hierbas y suplementos que también podrían retardar la coagulación sanguínea podría aumentar el riesgo de hemorragia o hematomas. Estas hierbas incluyen la angélica, el clavo de olor, la salvia miltiorrhiza, la matricaria, el ajo, el jengibre, el ginkgo, el ginseng Panax, el castaño de Indias, el trébol rojo, la cúrcuma y otras.

¿Existen interacciones con alimentos?

No se conoce ninguna interacción con alimentos.

¿Qué dosis se utiliza?

La dosis apropiada del resveratrol depende de muchos factores tales como la edad de la persona, el estado de salud y varias otras condiciones. En este momento no hay suficiente información científica para determinar un rango de dosis apropiado para el uso del resveratrol. Tenga en mente que los productos naturales no son siempre necesariamente seguros y las dosis pueden ser importantes. Asegúrese de seguir las instrucciones en las etiquetas de los productos y consulte con su farmacéutico, doctor u otro proveedor de salud médica antes de usarlos.

Otros nombres

3,5,4' TriHydroxy-Transstibene, (E)- 5-(4-hydroxystyryl)benzene-1,3-diol, 3,4',5-stilbenetriol, 3,5,4' -trihydroxystilbene, 3,4',5-trihydroxystilbene, 3,5,4'-trihydroxy-trans-stilbene, Cis-Resveratrol, Extrait de Vin, Extrait de Vin Rouge, Kojo-Kon, Phytoalexin, Phytoalexine, Phytoestrogen, Phyto-œstrogène, Pilule de Vin, Protykin, Red Wine Extract, Resvératrol, Resveratrols, Resvératrols, RSV, RSVL, Stilbene Phytoalexin, Trans-Resveratrol, Trans-Resvératrol, Wine Extract, Wine Pill.

Metodología

Para saber más sobre cómo este artículo fue escrito, refiérase a la metodología de la Base exhaustiva de datos de medicamentos naturales.

Referencias

  1. Hudson, G. M., Shelmadine, B., Cooke, M., Genovese, J., Greenwood, M., and Willoughby, D. S. Resveratrol Supplementation And Changes In Glucose, Insulin, And mRNA Expression Following Exercise In Overweight Females: 2467. Medicine & Science in Sports & Exercise 2011;43
  2. Guarnieri, R., Pappacoda, A., and Solitro, S. [A resveratrol containing compound reduces oxidative stress and ameliorates clinical symptoms in COPD subjects] Un composto a base di resveratrolo riduce lo stress ossidativo e migliora la sintomatologia clinica in soggetti con BPCO. Cochrane Central Register of Controlled Trials 2009;
  3. Gersting, J. A. Prostaglandin endoperoxide synthase types 1 and 2: Ontogenetic expression and effects of inhibition on the basal and estrogen stimulated fetal ovine hypothalamus-pituitary adrenal axis. The Sciences and Engineering 2011;71(8-B)
  4. Picchione, K. E. Understanding hyperexcitability of dorsal root ganglion neurons. The Sciences and Engineering 2011;72(4-B)
  5. Jackson, J. R. Resveratrol Preserves Muscles Mass, Force Output And Mediates Oxidative Stress In Gastrocnemius Muscles From Hindlimb Suspended Rats: 972. Medicine & Science in Sports & Exercise 2009;41
  6. Antonio, A. M. The protective effects of the antioxidant alpha-lipoic acid against ethanol-mediated toxicity in fetal rhombencephalic neurons. The Sciences and Engineering 2011;71(11-B)
  7. Kanamori, H., Takemura, G., Goto, K., Maruyama, R., Tsujimoto, A., Ogino, A., Takeyama, T., Kawaguchi, T., Watanabe, T., Morishita, K., Fujiwara, T., Fujiwara, H., Seishima, M., and Minatoguchi, S. Resveratrol Brings About Reverse Remodeling In The Heart With A Large Old Myocardial Infarction Through Autophagy Activating amp Kinase Pathway. Circulation 2011;124
  8. Kuno, A., Hori, Y., Tanno, M., Kouzu, H., Takahito, I., Daisuke, S., Yoshiyuki, H., and Tetsuji, M. Long-Term Treatment with the SIRT1 Activator Resveratrol Ameliorates Cardiomyopathy in Dystrophin-Deficient Mice. Circulation 2011;124
  9. Gordon, B. S. Resveratrol's Effect On Inflammation Associated With Muscle Degeneration/regeneration: A Dosage Trial: 1614. Medicine & Science in Sports & Exercise 2011;
  10. Quero, L., Klawitter, M., Plewnia, A., Klasen, J., Boos, N., and Wuertz, K. NOVEL TREATMENT OPTIONS FOR DISCOGENIC BACK PAIN: THE RED WINE POLYPHENOL RESVERATROL INHIBITS EXPRESSION OF PROINFLAMMATORY CYTOKINES AND MATRIX DEGRADING ENZYMES IN INTERVERTEBRAL DISC CELLS: GP12. Spine: Affiliated Society Meeting Abstracts 2010;
  11. Samuel, S. K., Kai, L., and Levenson, A. S. A NOVEL EPIGENETIC MECHANISM OF RESVERATROL: REVERSAL OF METASTASIS-ASSOCIATED PROTEIN 1-MEDIATED DEACETYLATION OF P53 IN PROSTATE CANCER: 1441. Journal of Urology 2009;181:515.
  12. Yoon, S. J., Cho, K. S., Lee, Y. H., Kim, D. S., and Hong, S. J. RESVERATROL INHIBITS CXCR4 MEDIATED TUMOR GROWTH AND MIGRATION OF HUMAN KIDNEY CANCER CELL IN VITRO AND IN VIVO: 428. Journal of Urology 2009;181:153-154.
  13. Klink, J. C., Poulton, S., Antonelli, J., Potter, M. Q., Jayachandran, J., Tewari, A. K., Febbo, P. G., Pizzo, S. V., and Freedland, S. RESVERATROL ALTERS PROSTATE CANCER XENOGRAFT GROWTH: 724. Journal of Urology 2009;181
  14. Schreiber, L., McAnulty, S., McAnulty, L., Rowe, B., Hosick, P., Wrieden, J., Hudson, M., Quindry, J., Nieman, D., and Henson, D. Resveratrol and Catechin Administration Blunts Exercise-Induced Oxidative Stress and Cytokine IL-8: 1570. Medicine & Science in Sports & Exercise 2008;40:S246.
  15. Sommer, S. P., Sommer, S., Sinha, B., Schafer, D., Otto, C., Aleksic, I., Mehdorn, A. S., and Leyh, R. Resveratrol Ameliorates Mitochondrial and Tissue Damage in Pulmonary Ischemia Reperfusion Injury. CHEST journal 2011;140:659A.
  16. Chung, H. R., Tomayko, E. J., Wu, P. T., Cachia, A. J., Cortez, F. T., and Wilund, K. R. Resveratrol and Exercise May Improve Kidney Disease Co-morbidities in a Model of Uremia. Medicine & Science in Sports & Exercise 2010;
  17. Fukuhara, S., Okuda, H., Yamamoto, K., Nakayama, J., Takao, T., Miyagawa, Y., Tsujimura, A., Nonomura, N., and Okuyama, A. RESVERATROL, A POLYPHENOLIC SIRT1 ACTIVATOR, IMPROVES ERECTILE FUNCTION IN STREPTOZOTOCIN INDUCED DIABETIC RATS: 875. Journal of Urology 2010;
  18. Seely, K. A. Cannabinoid receptor inverse agonists as novel therapeutic agents." The Sciences and Engineering. The Sciences and Engineering 2009;70(4-B)
  19. Han, Y. N., Ryn, S. Y., and Han, B. H. Antioxidant activity of resveratrol closely correlated with its monoamine oxidase-A inhibitory activity. Arch.Pharmacol.Res. 1990;13:132.
  20. Pregliasco, F. and Cogo, R. [Antioxidant and immunomodulating compounds in older people undergoing seasonal influenza vaccination improve serological response and reduce tract respiratory episodes] L'uso di sostanze antiossidanti ed immunomodulanti in una popolazione anziana so. Cochrane Central Register of Controlled Trials 2010;
  21. Steigerwald, M. D., Fisk, M. Z., Smoliga, J. M., and Rundell, K. W. Effects Of Resveratrol On Oxidative Stress And Vascular Function Following Exercise In Simulated Air Pollution: 2645. Medicine & Science in Sports & Exercise 2011;43
  22. Bost, J., Smoliga, J. M., Bost, K. M., and Maroon, J. C. Three Months Oral Supplementation of a Unique Polyphenol Mixture Improves Physical and Neurocognitive Performance Indicators in Sedentary Adults: 2205. Medicine & Science in Sports & Exercise 2008;40:S246.
  23. Grujic Milanovic, J., Mihailovic-Stanojevic, N., Miloradovic, Z., Jacevic, V., Milosavljevic, I., Milanovic, S., Ivanov, M., and Jovovic, D. J. RESVERATROL REDUCES BLOOD PRESSURE, CHANGES OF ANTIOXIDANT ENZYME ACTIVITY AND HISTOLOGICAL PARAMETERS IN EXPERIMENTAL MODEL OF MALIGNANT HYPERTENSION PP.29.171. Journal of Hypertension 2010;28
  24. Jackson, J., Ryan, M. J., and Hao, Y. Long-Term Resveratrol Supplementation Mediates Oxidative Stress, but not Sarcopenia Aged Mice: 2814. Medicine & Science in Sports & Exercise 2010;
  25. Marques, L., Bargut, T., Pires, L., Lopes, G., Eleutherio, E., Donangelo, C., and Koury, J. Resveratrol Supplementation, Immunological Indices And Total Antioxidant Capacity In Athletes: 2089. Medicine & Science in Sports & Exercise 2009;41
  26. Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler.Thromb.Vasc.Biol 1999;19:419-426. View abstract.
  27. Ciolino, H. P., Daschner, P. J., and Yeh, G. C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 12-15-1998;58:5707-5712. View abstract.
  28. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J.Biol.Chem. 8-21-1998;273:21875-21882. View abstract.
  29. Rotondo, S., Rajtar, G., Manarini, S., Celardo, A., Rotillo, D., de Gaetano, G., Evangelista, V., and Cerletti, C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br.J.Pharmacol. 1998;123:1691-1699. View abstract.
  30. Mgbonyebi, O. P., Russo, J., and Russo, I. H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int.J.Oncol. 1998;12:865-869. View abstract.
  31. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C., and Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1-16-1998;421:277-279. View abstract.
  32. Orsini, F., Pelizzoni, F., Verotta, L., Aburjai, T., and Rogers, C. B. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J.Nat.Prod. 1997;60:1082-1087. View abstract.
  33. Cheung, T. M., Ganatra, M. P., Peters, E. B., and Truskey, G. A. Effect of cellular senescence on the albumin permeability of blood-derived endothelial cells. Am.J.Physiol Heart Circ.Physiol 12-1-2012;303:H1374-H1383. View abstract.
  34. Bhatt, J. K., Thomas, S., and Nanjan, M. J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr.Res. 2012;32:537-541. View abstract.
  35. Hector, K. L., Lagisz, M., and Nakagawa, S. The effect of resveratrol on longevity across species: a meta-analysis. Biol.Lett. 10-23-2012;8:790-793. View abstract.
  36. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R. M., Martinez-Gonzalez, M. A., Salas-Salvado, J., Aros, F., Fito, M., Lapetra, J., Estruch, R., and Andres-Lacueva, C. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol.Res. 2012;65:615-620. View abstract.
  37. Timmers, S., Auwerx, J., and Schrauwen, P. The journey of resveratrol from yeast to human. Aging (Albany.NY) 2012;4:146-158. View abstract.
  38. Aluyen, J. K., Ton, Q. N., Tran, T., Yang, A. E., Gottlieb, H. B., and Bellanger, R. A. Resveratrol: potential as anticancer agent. J.Diet.Suppl 2012;9:45-56. View abstract.
  39. Zhu, W., Qin, W., Zhang, K., Rottinghaus, G. E., Chen, Y. C., Kliethermes, B., and Sauter, E. R. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr.Cancer 2012;64:393-400. View abstract.
  40. Roehr, B. Cardiovascular researcher fabricated data in studies of red wine. BMJ 2012;344:e406. View abstract.
  41. Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., and Barzilai, N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J.Gerontol.A Biol.Sci.Med.Sci. 2012;67:1307-1312. View abstract.
  42. Wang, Z., Li, W., Meng, X., and Jia, B. Resveratrol induces gastric cancer cell apoptosis via reactive oxygen species, but independent of sirtuin1. Clin.Exp.Pharmacol.Physiol 2012;39:227-232. View abstract.
  43. Girbovan, C., Morin, L., and Plamondon, H. Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav.Pharmacol. 2012;23:1-13. View abstract.
  44. Lukiw, W. J. NF-small ka, CyrillicB-regulated micro RNAs (miRNAs) in primary human brain cells. Exp.Neurol. 2012;235:484-490. View abstract.
  45. Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., Nishikawa, M., Iwasaka, T., and Das, D. K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr.Res 2011;31:842-847. View abstract.
  46. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., Moonen-Kornips, E., Hesselink, M. K., Kunz, I., Schrauwen-Hinderling, V. B., Blaak, E. E., Auwerx, J., and Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 11-2-2011;14:612-622. View abstract.
  47. Kiskova, T., Ekmekcioglu, C., Garajova, M., Orendas, P., Bojkova, B., Bobrov, N., Jager, W., Kassayova, M., and Thalhammer, T. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Eur.J Cancer Prev. 2012;21:163-170. View abstract.
  48. Di, Liberto, V, Makela, J., Korhonen, L., Olivieri, M., Tselykh, T., Malkia, A., Do, Thi H., Belluardo, N., Lindholm, D., and Mudo, G. Involvement of estrogen receptors in the resveratrol-mediated increase in dopamine transporter in human dopaminergic neurons and in striatum of female mice. Neuropharmacology 2012;62:1011-1018. View abstract.
  49. Yanez, M., Galan, L., Matias-Guiu, J., Vela, A., Guerrero, A., and Garcia, A. G. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 11-14-2011;1423:77-86. View abstract.
  50. Xuzhu, G., Komai-Koma, M., Leung, B. P., Howe, H. S., McSharry, C., McInnes, I. B., and Xu, D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann.Rheum.Dis 2012;71:129-135. View abstract.
  51. Knight, C. M., Gutierrez-Juarez, R., Lam, T. K., Arrieta-Cruz, I., Huang, L., Schwartz, G., Barzilai, N., and Rossetti, L. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 2011;60:2691-2700. View abstract.
  52. Das, J., Pany, S., and Majhi, A. Chemical modifications of resveratrol for improved protein kinase C alpha activity. Bioorg.Med Chem. 9-15-2011;19:5321-5333. View abstract.
  53. Dolinsky, V. W., Rueda-Clausen, C. F., Morton, J. S., Davidge, S. T., and Dyck, J. R. Continued postnatal administration of resveratrol prevents diet-induced metabolic syndrome in rat offspring born growth restricted. Diabetes 2011;60:2274-2284. View abstract.
  54. Stefanska, B., Salame, P., Bednarek, A., and Fabianowska-Majewska, K. Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br.J.Nutr. 2012;107:781-790. View abstract.
  55. Burgess, T. A., Robich, M. P., Chu, L. M., Bianchi, C., and Sellke, F. W. Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch.Surg. 2011;146:556-564. View abstract.
  56. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H. Y., Ma, Q. Y., Mukhopadhyay, P., Nalini, N., Pezzuto, J. M., Richard, T., Shukla, Y., Surh, Y. J., Szekeres, T., Szkudelski, T., Walle, T., and Wu, J. M. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS.One. 2011;6:e19881. View abstract.
  57. Snyder, S. A., Gollner, A., and Chiriac, M. I. Regioselective reactions for programmable resveratrol oligomer synthesis. Nature 6-23-2011;474:461-466. View abstract.
  58. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., and Gescher, A. J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev.Res (Phila) 2011;4:1419-1425. View abstract.
  59. Santos, A. C., Veiga, F., and Ribeiro, A. J. New delivery systems to improve the bioavailability of resveratrol. Expert.Opin.Drug Deliv. 2011;8:973-990. View abstract.
  60. Bastianetto, S., Krantic, S., Chabot, J. G., and Quirion, R. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols. Curr.Alzheimer Res 2011;8:445-451. View abstract.
  61. Wuertz, K., Quero, L., Sekiguchi, M., Klawitter, M., Nerlich, A., Konno, S., Kikuchi, S., and Boos, N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976.) 10-1-2011;36:E1373-E1384. View abstract.
  62. Kaneko, H., Anzai, T., Morisawa, M., Kohno, T., Nagai, T., Anzai, A., Takahashi, T., Shimoda, M., Sasaki, A., Maekawa, Y., Yoshimura, K., Aoki, H., Tsubota, K., Yoshikawa, T., Okada, Y., Ogawa, S., and Fukuda, K. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011;217:350-357. View abstract.
  63. Bhattacharya, S., Darjatmoko, S. R., and Polans, A. S. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res 2011;21:180-187. View abstract.
  64. Das, D. K., Mukherjee, S., and Ray, D. Erratum to: resveratrol and red wine, healthy heart and longevity. Heart Fail.Rev. 2011;16:425-435. View abstract.
  65. Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Szijarto, I. A., Merei, A., Halmai, R., Meszaros, L. G., Sumegi, B., and Wittmann, I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383-389. View abstract.
  66. Ungvari, Z., Sonntag, W. E., de, Cabo R., Baur, J. A., and Csiszar, A. Mitochondrial protection by resveratrol. Exerc.Sport Sci.Rev. 2011;39:128-132. View abstract.
  67. Fabbrocini, G., Staibano, S., De, Rosa G., Battimiello, V., Fardella, N., Ilardi, G., La Rotonda, M. I., Longobardi, A., Mazzella, M., Siano, M., Pastore, F., De, Vita, V, Vecchione, M. L., and Ayala, F. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am J Clin.Dermatol 4-1-2011;12:133-141. View abstract.
  68. Ghanim, H., Sia, C. L., Korzeniewski, K., Lohano, T., Abuaysheh, S., Marumganti, A., Chaudhuri, A., and Dandona, P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin.Endocrinol.Metab 2011;96:1409-1414. View abstract.
  69. Kitada, M., Kume, S., Imaizumi, N., and Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011;60:634-643. View abstract.
  70. Mukhopadhyay, P., Pacher, P., and Das, D. K. MicroRNA signatures of resveratrol in the ischemic heart. Ann.N.Y.Acad.Sci. 2011;1215:109-116. View abstract.
  71. Petrovski, G., Gurusamy, N., and Das, D. K. Resveratrol in cardiovascular health and disease. Ann.N.Y.Acad.Sci. 2011;1215:22-33. View abstract.
  72. Hsu, M. H., Savas, U., Lasker, J. M., and Johnson, E. F. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J Pharmacol.Exp.Ther 2011;337:125-136. View abstract.
  73. Yu, H. P., Hwang, T. L., Hsieh, P. W., and Lau, Y. T. Role of estrogen receptor-dependent upregulation of P38 MAPK/heme oxygenase 1 in resveratrol-mediated attenuation of intestinal injury after trauma-hemorrhage. Shock 2011;35:517-523. View abstract.
  74. Busanello, A., Barbosa, N. B., Peroza, L. R., Farias, L. E., Burger, M. E., Barreto, K. P., and Fachinetto, R. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav.Pharmacol. 2011;22:71-75. View abstract.
  75. Das, D. K. Commentary on 'resveratrol commonly displays hormesis: occurrence and biomedical significance' by Calabrese et al. Hum.Exp.Toxicol. 2010;29:1016-1017. View abstract.
  76. Shindler, K. S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D. C., and Rostami, A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010;30:328-339. View abstract.
  77. Seo, J. S., Moon, M. H., Jeong, J. K., Seol, J. W., Lee, Y. J., Park, B. H., and Park, S. Y. SIRT1, a histone deacetylase, regulates prion protein-induced neuronal cell death. Neurobiol.Aging 2012;33:1110-1120. View abstract.
  78. Xiang, H., Dai, K., Luo, Q., Duan, W., and Xie, Y. A sensitive resveratrol assay with a simple probe methylene blue by resonance light scattering technique. Spectrochim.Acta A Mol.Biomol.Spectrosc. 2011;78:307-312. View abstract.
  79. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J., and Brenner, D. E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 11-15-2010;70:9003-9011. View abstract.
  80. Guha, P., Dey, A., Sen, R., Chatterjee, M., Chattopadhyay, S., and Bandyopadhyay, S. K. Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol.Exp.Ther 2011;336:206-214. View abstract.
  81. Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., Brenner, D. E., Steward, W. P., Gescher, A. J., and Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 10-1-2010;70:7392-7399. View abstract.
  82. Robich, M. P., Osipov, R. M., Nezafat, R., Feng, J., Clements, R. T., Bianchi, C., Boodhwani, M., Coady, M. A., Laham, R. J., and Sellke, F. W. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 9-14-2010;122(11 Suppl):S142-S149. View abstract.
  83. Knobloch, J., Sibbing, B., Jungck, D., Lin, Y., Urban, K., Stoelben, E., Strauch, J., and Koch, A. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol.Exp.Ther 2010;335:788-798. View abstract.
  84. Chow, H. H., Garland, L. L., Hsu, C. H., Vining, D. R., Chew, W. M., Miller, J. A., Perloff, M., Crowell, J. A., and Alberts, D. S. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev.Res (Phila) 2010;3:1168-1175. View abstract.
  85. Perdew, G. H., Hollingshead, B. D., Dinatale, B. C., Morales, J. L., Labrecque, M. P., Takhar, M. K., Tam, K. J., and Beischlag, T. V. Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity. J Pharmacol.Exp.Ther 2010;335:273-283. View abstract.
  86. Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M., Kunz, I., and Berry, N. M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr.Metab Cardiovasc.Dis 2011;21:851-856. View abstract.
  87. Dubey, R. K., Jackson, E. K., Gillespie, D. G., Zacharia, L. C., Imthurn, B., and Rosselli, M. Resveratrol, a red wine constituent, blocks the antimitogenic effects of estradiol on human female coronary artery smooth muscle cells. J Clin.Endocrinol.Metab 2010;95:E9-17. View abstract.
  88. Ghanim, H., Sia, C. L., Abuaysheh, S., Korzeniewski, K., Patnaik, P., Marumganti, A., Chaudhuri, A., and Dandona, P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin.Endocrinol.Metab 2010;95:E1-E8. View abstract.
  89. la, Porte C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., and Cameron, D. W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin.Pharmacokinet. 2010;49:449-454. View abstract.
  90. Guha, P., Dey, A., Dhyani, M. V., Sen, R., Chatterjee, M., Chattopadhyay, S., and Bandyopadhyay, S. K. Calpain and caspase orchestrated death signal to accomplish apoptosis induced by resveratrol and its novel analog hydroxystilbene-1 [correction of hydroxstilbene-1] in cancer cells. J Pharmacol.Exp.Ther 2010;334:381-394. View abstract.
  91. Le Couteur, D. G. and Sinclair, D. A. A blueprint for developing therapeutic approaches that increase healthspan and delay death. J Gerontol.A Biol.Sci.Med Sci. 2010;65:693-694. View abstract.
  92. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., and Haskell, C. F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin.Nutr. 2010;91:1590-1597. View abstract.
  93. Daffner, K. R. Promoting successful cognitive aging: a comprehensive review. J Alzheimers.Dis 2010;19:1101-1122. View abstract.
  94. Sun, A. Y., Wang, Q., Simonyi, A., and Sun, G. Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol.Neurobiol. 2010;41(2-3):375-383. View abstract.
  95. Das, D. K., Mukherjee, S., and Ray, D. Resveratrol and red wine, healthy heart and longevity. Heart Fail.Rev. 2010;15:467-477. View abstract.
  96. Fullerton, M. D. and Steinberg, G. R. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010;59:551-553. View abstract.
  97. Huang, P. H., Chen, Y. H., Tsai, H. Y., Chen, J. S., Wu, T. C., Lin, F. Y., Sata, M., Chen, J. W., and Lin, S. J. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arterioscler.Thromb.Vasc.Biol. 2010;30:869-877. View abstract.
  98. Yu, H. P., Hwang, T. L., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol prevents endothelial dysfunction and aortic superoxide production after trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway. Crit Care Med 2010;38:1147-1154. View abstract.
  99. Albani, D., Polito, L., and Forloni, G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers.Dis 2010;19:11-26. View abstract.
  100. Guo, J. P., Yu, S., and McGeer, P. L. Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimers.Dis. 2010;19:1359-1370. View abstract.
  101. Kim, J., Lee, H. J., and Lee, K. W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem. 2010;112:1415-1430. View abstract.
  102. Gagliano, N., Aldini, G., Colombo, G., Rossi, R., Colombo, R., Gioia, M., Milzani, A., and Dalle-Donne, I. The potential of resveratrol against human gliomas. Anticancer Drugs 2010;21:140-150. View abstract.
  103. Um, J. H., Park, S. J., Kang, H., Yang, S., Foretz, M., McBurney, M. W., Kim, M. K., Viollet, B., and Chung, J. H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554-563. View abstract.
  104. Ramadori, G., Gautron, L., Fujikawa, T., Vianna, C. R., Elmquist, J. K., and Coppari, R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009;150:5326-5333. View abstract.
  105. Jha, R. K., Ma, Q., Sha, H., and Palikhe, M. Protective effect of resveratrol in severe acute pancreatitis-induced brain injury. Pancreas 2009;38:947-953. View abstract.
  106. Csiszar, A., Labinskyy, N., Olson, S., Pinto, J. T., Gupte, S., Wu, J. M., Hu, F., Ballabh, P., Podlutsky, A., Losonczy, G., de, Cabo R., Mathew, R., Wolin, M. S., and Ungvari, Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009;54:668-675. View abstract.
  107. Ranney, A. and Petro, M. S. Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav.Pharmacol. 2009;20:330-336. View abstract.
  108. Zhang, H., Zhang, J., Ungvari, Z., and Zhang, C. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler.Thromb.Vasc.Biol. 2009;29:1164-1171. View abstract.
  109. Bournival, J., Quessy, P., and Martinoli, M. G. Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol.Neurobiol. 2009;29:1169-1180. View abstract.
  110. Woodall, C. E., Li, Y., Liu, Q. H., Wo, J., and Martin, R. C. Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anticancer Drugs 2009;20:437-443. View abstract.
  111. Dolinsky, V. W., Chan, A. Y., Robillard, Frayne, I, Light, P. E., Des, Rosiers C., and Dyck, J. R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 3-31-2009;119:1643-1652. View abstract.
  112. Bastianetto, S., Dumont, Y., Han, Y., and Quirion, R. Comparative neuroprotective properties of stilbene and catechin analogs: action via a plasma membrane receptor site? CNS.Neurosci.Ther 2009;15:76-83. View abstract.
  113. Mainardi, T., Kapoor, S., and Bielory, L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin.Immunol. 2009;123:283-294. View abstract.
  114. Almeida, L., Vaz-da-Silva, M., Falcao, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J. F., Nunes, T., Wright, L., and Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol.Nutr.Food Res 2009;53 Suppl 1:S7-15. View abstract.
  115. Vingtdeux, V., Dreses-Werringloer, U., Zhao, H., Davies, P., and Marambaud, P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC.Neurosci. 2008;9 Suppl 2:S6. View abstract.
  116. Fan, E., Zhang, L., Jiang, S., and Bai, Y. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008;11:610-614. View abstract.
  117. Valderrama, X., Rapin, N., and Misra, V. Zhangfei, a novel regulator of the human nerve growth factor receptor, trkA. J Neurovirol. 2008;14:425-436. View abstract.
  118. Li, X., Phillips, F. M., An, H. S., Ellman, M., Thonar, E. J., Wu, W., Park, D., and Im, H. J. The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine (Phila Pa 1976.) 11-15-2008;33:2586-2595. View abstract.
  119. Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T., Rocha, J. F., Fernandes-Lopes, C., Soares, E., Wright, L., Almeida, L., and Soares-da-Silva, P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int.J Clin.Pharmacol.Ther 2008;46:564-570. View abstract.
  120. Askanas, V. and Engel, W. K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol. 2008;116:583-595. View abstract.
  121. Rimando, A. M. and Suh, N. Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med 2008;74:1635-1643. View abstract.
  122. Knutson, M. D. and Leeuwenburgh, C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr.Rev. 2008;66:591-596. View abstract.
  123. Dudley, J. I., Lekli, I., Mukherjee, S., Das, M., Bertelli, A. A., and Das, D. K. Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric.Food Chem. 10-22-2008;56:9362-9373. View abstract.
  124. Kris-Etherton, P. M., Hu, F. B., Ros, E., and Sabate, J. The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms. J Nutr. 2008;138:1746S-1751S. View abstract.
  125. Gresele, P., Pignatelli, P., Guglielmini, G., Carnevale, R., Mezzasoma, A. M., Ghiselli, A., Momi, S., and Violi, F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr. 2008;138:1602-1608. View abstract.
  126. Orallo, F. Trans-resveratrol: a magical elixir of eternal youth? Curr.Med Chem. 2008;15:1887-1898. View abstract.
  127. Rocha-Gonzalez, H. I., Ambriz-Tututi, M., and Granados-Soto, V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS.Neurosci.Ther 2008;14:234-247. View abstract.
  128. Udenigwe, C. C., Ramprasath, V. R., Aluko, R. E., and Jones, P. J. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr.Rev. 2008;66:445-454. View abstract.
  129. Roupe, K. A., Remsberg, C. M., Yanez, J. A., and Davies, N. M. Pharmacometrics of stilbenes: seguing towards the clinic. Curr.Clin.Pharmacol. 2006;1:81-101. View abstract.
  130. Fan, E., Jiang, S., Zhang, L., and Bai, Y. Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent. Int.J Vitam.Nutr.Res 2008;78:3-8. View abstract.
  131. Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., and Rizzarelli, E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem.Res 2008;33:2444-2471. View abstract.
  132. Singletary, K. and Milner, J. Diet, autophagy, and cancer: a review. Cancer Epidemiol.Biomarkers Prev. 2008;17:1596-1610. View abstract.
  133. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., Swindell, W. R., Kamara, D., Minor, R. K., Perez, E., Jamieson, H. A., Zhang, Y., Dunn, S. R., Sharma, K., Pleshko, N., Woollett, L. A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P. J., Becker, K. G., Navas, P., Ingram, D. K., Wolf, N. S., Ungvari, Z., Sinclair, D. A., and de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-168. View abstract.
  134. Jiang, W. J. Sirtuins: novel targets for metabolic disease in drug development. Biochem.Biophys.Res Commun. 8-29-2008;373:341-344. View abstract.
  135. Dong, W., Li, N., Gao, D., Zhen, H., Zhang, X., and Li, F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc.Surg. 2008;48:709-714. View abstract.
  136. Venkatesan, B., Ghosh-Choudhury, N., Das, F., Mahimainathan, L., Kamat, A., Kasinath, B. S., Abboud, H. E., and Choudhury, G. G. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J 2008;22:3469-3482. View abstract.
  137. Kundu, J. K. and Surh, Y. J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 10-8-2008;269:243-261. View abstract.
  138. Liu, L., Wang, Y., Lam, K. S., and Xu, A. Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr.Metab Immune.Disord Drug Targets. 2008;8:89-98. View abstract.
  139. Raval, A. P., Lin, H. W., Dave, K. R., Defazio, R. A., Della, Morte D., Kim, E. J., and Perez-Pinzon, M. A. Resveratrol and ischemic preconditioning in the brain. Curr.Med Chem. 2008;15:1545-1551. View abstract.
  140. Zheng, G. H. and Li, H. Q. [Effects of garlic oil combined with resveratrol on inducting of apoptosis and expression of Fas, bcl-2 and bax in human gastric cancer cell line]. Zhonghua Yu Fang Yi.Xue.Za Zhi. 2008;42:39-42. View abstract.
  141. Deng, J. Y., Hsieh, P. S., Huang, J. P., Lu, L. S., and Hung, L. M. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008;57:1814-1823. View abstract.
  142. Pirola, L. and Frojdo, S. Resveratrol: one molecule, many targets. IUBMB.Life 2008;60:323-332. View abstract.
  143. Guarente, L. Sirtuins in aging and disease. Cold Spring Harb.Symp.Quant.Biol. 2007;72:483-488. View abstract.
  144. Rossi, L., Mazzitelli, S., Arciello, M., Capo, C. R., and Rotilio, G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem.Res 2008;33:2390-2400. View abstract.
  145. Elliott, P. J. and Jirousek, M. Sirtuins: novel targets for metabolic disease. Curr.Opin.Investig.Drugs 2008;9:371-378. View abstract.
  146. Biswas, S. and Rahman, I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol.Nutr.Food Res 2008;52:987-994. View abstract.
  147. Chen, C. Y. and Blumberg, J. B. Phytochemical composition of nuts. Asia Pac.J Clin.Nutr. 2008;17 Suppl 1:329-332. View abstract.
  148. Yu, H. P., Hsu, J. C., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock 2008;30:324-328. View abstract.
  149. Nicholson, S. K., Tucker, G. A., and Brameld, J. M. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc.Nutr.Soc 2008;67:42-47. View abstract.
  150. Das, S. and Das, D. K. Anti-inflammatory responses of resveratrol. Inflamm.Allergy Drug Targets. 2007;6:168-173. View abstract.
  151. Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech.Ageing Dev 2007;128:546-552. View abstract.
  152. Gruber, J., Tang, S. Y., and Halliwell, B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y.Acad Sci 2007;1100:530-542. View abstract.
  153. Fragopoulou, E., Nomikos, T., Karantonis, H. C., Apostolakis, C., Pliakis, E., Samiotaki, M., Panayotou, G., and Antonopoulou, S. Biological activity of acetylated phenolic compounds. J.Agric.Food Chem. 1-10-2007;55:80-89. View abstract.
  154. Baur, J. A. and Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506. View abstract.
  155. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R. M., Estruch, R., Vazquez-Agell, M., Serrano-Martinez, M., Jaeger, W., and Andres-Lacueva, C. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin.Chem. 2006;52:1373-1380. View abstract.
  156. Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., and Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2-7-2006;16:296-300. View abstract.
  157. Cruz, M. N., Luksha, L., Logman, H., Poston, L., Agewall, S., and Kublickiene, K. Acute responses to phytoestrogens in small arteries from men with coronary heart disease. Am J Physiol Heart Circ.Physiol 2006;290:H1969-H1975. View abstract.
  158. Rakici, O., Kiziltepe, U., Coskun, B., Aslamaci, S., and Akar, F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int.J Cardiol 11-2-2005;105:209-215. View abstract.
  159. Ishii, Y., Ishida, T., Mutoh, J., Yamada, H., and Oguri, K. [Possible candidates for the compound which is expected to attenuate dioxin toxicity]. Fukuoka Igaku Zasshi 2005;96:204-213. View abstract.
  160. Jung, H. J., Hwang, I. A., Sung, W. S., Kang, H., Kang, B. S., Seu, Y. B., and Lee, D. G. Fungicidal effect of resveratrol on human infectious fungi. Arch Pharm Res 2005;28:557-560. View abstract.
  161. Deby-Dupont, G., Mouithys-Mickalad, A., Serteyn, D., Lamy, M., and Deby, C. Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. Biochem.Biophys.Res Commun. 7-22-2005;333:21-27. View abstract.
  162. Hougee, S., Faber, J., Sanders, A., de Jong, R. B., van den Berg, W. B., Garssen, J., Hoijer, M. A., and Smit, H. F. Selective COX-2 inhibition by a Pterocarpus marsupium extract characterized by pterostilbene, and its activity in healthy human volunteers. Planta Med 2005;71:387-392. View abstract.
  163. Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11:3171-3174. View abstract.
  164. Poolman, T. M., Ng, L. L., Farmer, P. B., and Manson, M. M. Inhibition of the respiratory burst by resveratrol in human monocytes: correlation with inhibition of PI3K signaling. Free Radic.Biol.Med. 7-1-2005;39:118-132. View abstract.
  165. Galfi, P., Jakus, J., Molnar, T., Neogrady, S., and Csordas, A. Divergent effects of resveratrol, a polyphenolic phytostilbene, on free radical levels and type of cell death induced by the histone deacetylase inhibitors butyrate and trichostatin A. J Steroid Biochem.Mol.Biol. 2005;94(1-3):39-47. View abstract.
  166. Azios, N. G. and Dharmawardhane, S. F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia. 2005;7:128-140. View abstract.
  167. Monthakantirat, O., De Eknamkul, W., Umehara, K., Yoshinaga, Y., Miyase, T., Warashina, T., and Noguchi, H. Phenolic constituents of the rhizomes of the Thai medicinal plant Belamcanda chinensis with proliferative activity for two breast cancer cell lines. J Nat Prod. 2005;68:361-364. View abstract.
  168. Molnar, V. and Garai, J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int.Immunopharmacol. 2005;5:849-856. View abstract.
  169. Belleri, M., Ribatti, D., Nicoli, S., Cotelli, F., Forti, L., Vannini, V., Stivala, L. A., and Presta, M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol.Pharmacol 2005;67:1451-1459. View abstract.
  170. Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., and Smorlesi, A. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int.J Cancer 5-20-2005;115:36-45. View abstract.
  171. Pozo-Guisado, E., Merino, J. M., Mulero-Navarro, S., Lorenzo-Benayas, M. J., Centeno, F., Alvarez-Barrientos, A., and Fernandez-Salguero, P. M. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 5-20-2005;115:74-84. View abstract.
  172. Henry, C., Vitrac, X., Decendit, A., Ennamany, R., Krisa, S., and Merillon, J. M. Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. J Agric.Food Chem 2-9-2005;53:798-803. View abstract.
  173. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., Bedalov, A., and Kennedy, B. K. Substrate-specific activation of sirtuins by resveratrol. J Biol.Chem 4-29-2005;280:17038-17045. View abstract.
  174. Baatout, S., Derradji, H., Jacquet, P., and Mergeay, M. Increased radiation sensitivity of an eosinophilic cell line following treatment with epigallocatechin-gallate, resveratrol and curcuma. Int.J Mol.Med. 2005;15:337-352. View abstract.
  175. Zhou, H. B., Chen, J. J., Wang, W. X., Cai, J. T., and Du, Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J.Gastroenterol. 1-14-2005;11:280-284. View abstract.
  176. Cao, Y., Fu, Z. D., Wang, F., Liu, H. Y., and Han, R. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod.Res 2005;7:205-213. View abstract.
  177. McCarty, M. F. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Med.Hypotheses 2005;64:628-635. View abstract.
  178. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., and Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840. View abstract.
  179. Shenouda, N. S., Zhou, C., Browning, J. D., Ansell, P. J., Sakla, M. S., Lubahn, D. B., and MacDonald, R. S. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr.Cancer 2004;49:200-208. View abstract.
  180. Bianco, N. R., Chaplin, L. J., and Montano, M. M. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem.J 1-1-2005;385(Pt 1):279-287. View abstract.
  181. Wang, Z., Hsieh, T. C., Zhang, Z., Ma, Y., and Wu, J. M. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem.Biophys.Res.Commun. 10-22-2004;323:743-749. View abstract.
  182. Seaver, B. and Smith, J. R. Inhibition of COX isoforms by nutraceuticals. J Herb.Pharmacother. 2004;4:11-18. View abstract.
  183. Buryanovskyy, L., Fu, Y., Boyd, M., Ma, Y., Hsieh, T. C., Wu, J. M., and Zhang, Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 9-14-2004;43:11417-11426. View abstract.
  184. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., and Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377-1382. View abstract.
  185. Jannin, B., Menzel, M., Berlot, J. P., Delmas, D., Lancon, A., and Latruffe, N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem.Pharmacol. 9-15-2004;68:1113-1118. View abstract.
  186. Evers, D. L., Wang, X., Huong, S. M., Huang, D. Y., and Huang, E. S. 3,4',5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res. 2004;63:85-95. View abstract.
  187. Cao, Z., Fang, J., Xia, C., Shi, X., and Jiang, B. H. trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin.Cancer Res 8-1-2004;10:5253-5263. View abstract.
  188. Piver, B., Fer, M., Vitrac, X., Merillon, J. M., Dreano, Y., Berthou, F., and Lucas, D. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem.Pharmacol. 8-15-2004;68:773-782. View abstract.
  189. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., and Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 8-5-2004;430:686-689. View abstract.
  190. Olas, B., Wachowicz, B., Bald, E., and Glowacki, R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J.Physiol Pharmacol. 2004;55:467-476. View abstract.
  191. Zhang, S., Cao, H. J., Davis, F. B., Tang, H. Y., Davis, P. J., and Lin, H. Y. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br.J.Cancer 7-5-2004;91:178-185. View abstract.
  192. Liu, J., Wang, Q., Wu, D. C., Wang, X. W., Sun, Y., Chen, X. Y., Zhang, K. L., and Li, H. Differential regulation of CYP1A1 and CYP1B1 expression in resveratrol-treated human medulloblastoma cells. Neurosci.Lett. 6-17-2004;363:257-261. View abstract.
  193. Laux, M. T., Aregullin, M., Berry, J. P., Flanders, J. A., and Rodriguez, E. Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol. J.Altern.Complement Med. 2004;10:235-239. View abstract.
  194. Berge, G., Ovrebo, S., Botnen, I. V., Hewer, A., Phillips, D. H., Haugen, A., and Mollerup, S. Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br.J.Cancer 7-19-2004;91:333-338. View abstract.
  195. Liontas, A. and Yeger, H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004;24(2B):987-998. View abstract.
  196. Chen, Z. H., Hurh, Y. J., Na, H. K., Kim, J. H., Chun, Y. J., Kim, D. H., Kang, K. S., Cho, M. H., and Surh, Y. J. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004;25:2005-2013. View abstract.
  197. Gehm, B. D., Levenson, A. S., Liu, H., Lee, E. J., Amundsen, B. M., Cushman, M., Jordan, V. C., and Jameson, J. L. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J.Steroid Biochem.Mol.Biol. 2004;88:223-234. View abstract.
  198. Ahmad, K. A., Clement, M. V., and Pervaiz, S. Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induced apoptosis. Ann.N.Y.Acad.Sci. 2003;1010:365-373. View abstract.
  199. Cheung, C. Y., Chen, J., and Chang, T. K. Evaluation of a real-time polymerase chain reaction method for the quantification of CYP1B1 gene expression in MCF-7 human breast carcinoma cells. J Pharmacol Toxicol.Methods 2004;49:97-104. View abstract.
  200. Cardile, V., Scifo, C., Russo, A., Falsaperla, M., Morgia, G., Motta, M., Renis, M., Imbriani, E., and Silvestre, G. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res. 2003;23(6C):4921-4926. View abstract.
  201. Sale, S., Verschoyle, R. D., Boocock, D., Jones, D. J., Wilsher, N., Ruparelia, K. C., Potter, G. A., Farmer, P. B., Steward, W. P., and Gescher, A. J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 2-9-2004;90:736-744. View abstract.
  202. Pozo-Guisado, E., Lorenzo-Benayas, M. J., and Fernandez-Salguero, P. M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int.J.Cancer 3-20-2004;109:167-173. View abstract.
  203. Stewart, J. R. and O'Brian, C. A. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 2004;22:107-117. View abstract.
  204. Fulda, S. and Debatin, K. M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 1-1-2004;64:337-346. View abstract.
  205. Li, Y., Shin, Y. G., Yu, C., Kosmeder, J. W., Hirschelman, W. H., Pezzuto, J. M., and van Breemen, R. B. Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism. Comb.Chem.High Throughput.Screen. 2003;6:757-767. View abstract.
  206. Kubota, T., Uemura, Y., Kobayashi, M., and Taguchi, H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res. 2003;23(5A):4039-4046. View abstract.
  207. Li, Y. T., Shen, F., Liu, B. H., and Cheng, G. F. Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Acta Pharmacol.Sin. 2003;24:1167-1171. View abstract.
  208. Inoue, H., Jiang, X. F., Katayama, T., Osada, S., Umesono, K., and Namura, S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci.Lett. 12-11-2003;352:203-206. View abstract.
  209. Liu, J. C., Chen, J. J., Chan, P., Cheng, C. F., and Cheng, T. H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003;42:1198-1205. View abstract.
  210. Mnjoyan, Z. H. and Fujise, K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem.Biophys.Res.Commun. 11-14-2003;311:546-552. View abstract.
  211. Lin, M. T., Yen, M. L., Lin, C. Y., and Kuo, M. L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol.Pharmacol. 2003;64:1029-1036. View abstract.
  212. Cavallaro, A., Ainis, T., Bottari, C., and Fimiani, V. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res. 2003;52:555-562. View abstract.
  213. Li, Y. T., Shen, F., Bai, J. Y., and Cheng, G. F. [Inhibition of dexamethasone, indomethacin and resveratrol on matrix metalloproteinase-9 and the mechanism of inhibition]. Yao Xue.Xue.Bao. 2003;38:501-504. View abstract.
  214. Kim, Y. A., Lee, W. H., Choi, T. H., Rhee, S. H., Park, K. Y., and Choi, Y. H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int.J.Oncol. 2003;23:1143-1149. View abstract.
  215. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 9-11-2003;425:191-196. View abstract.
  216. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N., and Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J.Biol.Chem. 10-17-2003;278:41482-41490. View abstract.
  217. Zhuang, H., Kim, Y. S., Koehler, R. C., and Dore, S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann.N Y.Acad.Sci. 2003;993:276-286. View abstract.
  218. Mahady, G. B., Pendland, S. L., and Chadwick, L. R. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am.J Gastroenterol. 2003;98:1440-1441. View abstract.
  219. Boscolo, P., del Signore, A., Sabbioni, E., Di Gioacchino, M., Di Giampaolo, L., Reale, M., Conti, P., Paganelli, R., and Giaccio, M. Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann.Clin.Lab Sci. 2003;33:226-231. View abstract.
  220. Aziz, M. H., Kumar, R., and Ahmad, N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int.J.Oncol. 2003;23:17-28. View abstract.
  221. El Mowafy, A. M. and Alkhalaf, M. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 2003;24:869-873. View abstract.
  222. Shen, F., Chen, S. J., Dong, X. J., Zhong, H., Li, Y. T., and Cheng, G. F. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J.Asian Nat.Prod.Res. 2003;5:151-157. View abstract.
  223. Gallo, R., Viglizzo, G., Vecchio, F., and Parodi, A. Allergic contact dermatitis from pentylene glycol in an emollient cream, with possible co-sensitization to resveratrol. Contact Dermatitis 2003;48:176-177. View abstract.
  224. Pellegatta, F., Bertelli, A. A., Staels, B., Duhem, C., Fulgenzi, A., and Ferrero, M. E. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am.J.Clin.Nutr. 2003;77:1220-1228. View abstract.
  225. Quinones, A., Dobberstein, K. U., and Rainov, N. G. The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci. 5-16-2003;72:2975-2992. View abstract.
  226. Estrov, Z., Shishodia, S., Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M., and Aggarwal, B. B. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 8-1-2003;102:987-995. View abstract.
  227. Wolter, F., Turchanowa, L., and Stein, J. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis 2003;24:469-474. View abstract.
  228. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., and Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem.Pharmacol. 4-1-2003;65:1053-1060. View abstract.
  229. Adhami, V. M., Afaq, F., and Ahmad, N. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia. 2003;5:74-82. View abstract.
  230. Klinge, C. M., Risinger, K. E., Watts, M. B., Beck, V., Eder, R., and Jungbauer, A. Estrogenic activity in white and red wine extracts. J Agric.Food Chem 3-26-2003;51:1850-1857. View abstract.
  231. Zhou, H. B., Yan, Y., Sun, Y. N., and Zhu, J. R. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J.Gastroenterol. 2003;9:408-411. View abstract.
  232. Gerhauser, C., Klimo, K., Heiss, E., Neumann, I., Gamal-Eldeen, A., Knauft, J., Liu, G. Y., Sitthimonchai, S., and Frank, N. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat.Res 2003;523-524:163-172. View abstract.
  233. Vitrac, X., Desmouliere, A., Brouillaud, B., Krisa, S., Deffieux, G., Barthe, N., Rosenbaum, J., and Merillon, J. M. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 4-4-2003;72:2219-2233. View abstract.
  234. Levenson, A. S., Gehm, B. D., Pearce, S. T., Horiguchi, J., Simons, L. A., Ward, J. E., III, Jameson, J. L., and Jordan, V. C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int.J.Cancer 5-1-2003;104:587-596. View abstract.
  235. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17:307-313. View abstract.
  236. Niles, R. M., McFarland, M., Weimer, M. B., Redkar, A., Fu, Y. M., and Meadows, G. G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 2-20-2003;190:157-163. View abstract.
  237. Liu, G. A. and Zheng, R. L. Protection against damaged DNA in the single cell by polyphenols. Pharmazie 2002;57:852-854. View abstract.
  238. Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., and van Breemen, R. B. Human, rat, and mouse metabolism of resveratrol. Pharm.Res. 2002;19:1907-1914. View abstract.
  239. Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. View abstract.
  240. Suttnar, J., Masova, L., Scheiner, T., Sorelova, V., and Dyr, J. E. [Role of free radicals in blood platelet activation]. Cas.Lek.Cesk. 9-22-2002;141 Suppl:47-49. View abstract.
  241. Brownson, D. M., Azios, N. G., Fuqua, B. K., Dharmawardhane, S. F., and Mabry, T. J. Flavonoid effects relevant to cancer. J Nutr. 2002;132(11 Suppl):3482S-3489S. View abstract.
  242. Kuo, P. L., Chiang, L. C., and Lin, C. C. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 11-22-2002;72:23-34. View abstract.
  243. Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S., Santiago-Josefat, B., and Fernandez-Salguero, P. M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem.Pharmacol. 11-1-2002;64:1375-1386. View abstract.
  244. Mahyar-Roemer, M., Kohler, H., and Roemer, K. Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells. BMC.Cancer 10-17-2002;2:27. View abstract.
  245. Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 9-24-2002;106:1652-1658. View abstract.
  246. Sharma, M. and Gupta, Y. K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 10-11-2002;71:2489-2498. View abstract.
  247. Yoon, S. H., Kim, Y. S., Ghim, S. Y., Song, B. H., and Bae, Y. S. Inhibition of protein kinase CKII activity by resveratrol, a natural compound in red wine and grapes. Life Sci. 9-20-2002;71:2145-2152. View abstract.
  248. Dobrydneva, Y., Williams, R. L., Morris, G. Z., and Blackmore, P. F. Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc.Pharmacol 2002;40:399-410. View abstract.
  249. Ferry-Dumazet, H., Garnier, O., Mamani-Matsuda, M., Vercauteren, J., Belloc, F., Billiard, C., Dupouy, M., Thiolat, D., Kolb, J. P., Marit, G., Reiffers, J., and Mossalayi, M. D. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 2002;23:1327-1333. View abstract.
  250. Lin, H. Y., Shih, A., Davis, F. B., Tang, H. Y., Martino, L. J., Bennett, J. A., and Davis, P. J. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J.Urol. 2002;168:748-755. View abstract.
  251. El Mowafy, A. M., Abou-Zeid, L. A., and Edafiogho, I. Recognition of resveratrol by the human estrogen receptor-alpha: a molecular modeling approach to understand its biological actions. Med.Princ.Pract. 2002;11:86-92. View abstract.
  252. Pietraforte, D., Turco, L., Azzini, E., and Minetti, M. On-line EPR study of free radicals induced by peroxidase/HO in human low-density lipoprotein. Biochim.Biophys Acta 7-11-2002;1583:176-184. View abstract.
  253. Sen, C. K., Khanna, S., Gordillo, G., Bagchi, D., Bagchi, M., and Roy, S. Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. Ann.N Y.Acad.Sci. 2002;957:239-249. View abstract.
  254. Ignatowicz, E. and Baer-Dubowska, W. Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol.J.Pharmacol. 2001;53:557-569. View abstract.
  255. Holian, O., Wahid, S., Atten, M. J., and Attar, B. M. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am.J.Physiol Gastrointest.Liver Physiol 2002;282:G809-G816. View abstract.
  256. Wang, Z., Zou, J., Huang, Y., Cao, K., Xu, Y., and Wu, J. M. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med.J.(Engl.) 2002;115:378-380. View abstract.
  257. Joe, A. K., Liu, H., Suzui, M., Vural, M. E., Xiao, D., and Weinstein, I. B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin.Cancer Res. 2002;8:893-903. View abstract.
  258. Baek, S. J., Wilson, L. C., and Eling, T. E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-434. View abstract.
  259. Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., and Burke, M. D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br.J.Cancer 3-4-2002;86:774-778. View abstract.
  260. Chan, M. M. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem.Pharmacol. 1-15-2002;63:99-104. View abstract.
  261. Sun, Z. J., Pan, C. E., Liu, H. S., and Wang, G. J. Anti-hepatoma activity of resveratrol in vitro. World J.Gastroenterol. 2002;8:79-81. View abstract.
  262. Serrero, G. and Lu, R. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid.Redox.Signal. 2001;3:969-979. View abstract.
  263. Bertelli, A. A., Baccalini, R., Battaglia, E., Falchi, M., and Ferrero, M. E. Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 2001;56:613-616. View abstract.
  264. Zou, J., Huang, Y., Chen, Q., Wei, E., Cao, K., and Wu, J. M. Effects of resveratrol on oxidative modification of human low density lipoprotein. Chin Med.J.(Engl.) 2000;113:99-102. View abstract.
  265. Falchetti, R., Fuggetta, M. P., Lanzilli, G., Tricarico, M., and Ravagnan, G. Effects of resveratrol on human immune cell function. Life Sci. 11-21-2001;70:81-96. View abstract.
  266. Bhavnani, B. R., Cecutti, A., Gerulath, A., Woolever, A. C., and Berco, M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause. 2001;8:408-419. View abstract.
  267. Atten, M. J., Attar, B. M., Milson, T., and Holian, O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem.Pharmacol. 11-15-2001;62:1423-1432. View abstract.
  268. Bhat, K. P., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 10-15-2001;61:7456-7463. View abstract.
  269. Lee, J. E. and Safe, S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem.Pharmacol. 10-15-2001;62:1113-1124. View abstract.
  270. Aumont, V., Krisa, S., Battaglia, E., Netter, P., Richard, T., Merillon, J. M., Magdalou, J., and Sabolovic, N. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch.Biochem.Biophys. 9-15-2001;393:281-289. View abstract.
  271. Sgambato, A., Ardito, R., Faraglia, B., Boninsegna, A., Wolf, F. I., and Cittadini, A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat.Res. 9-20-2001;496(1-2):171-180. View abstract.
  272. Yoon, K., Pallaroni, L., Stoner, M., Gaido, K., and Safe, S. Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements. J Steroid Biochem.Mol.Biol. 2001;78:25-32. View abstract.
  273. Bhat, K. P. and Pezzuto, J. M. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 8-15-2001;61:6137-6144. View abstract.
  274. Igura, K., Ohta, T., Kuroda, Y., and Kaji, K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 9-28-2001;171:11-16. View abstract.
  275. Wolter, F., Akoglu, B., Clausnitzer, A., and Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J.Nutr. 2001;131:2197-2203. View abstract.
  276. Subbaramaiah, K. and Dannenberg, A. J. Resveratrol inhibits the expression of cyclooxygenase-2 in mammary epithelial cells. Adv.Exp.Med.Biol. 2001;492:147-157. View abstract.
  277. Gusman, J., Malonne, H., and Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001;22:1111-1117. View abstract.
  278. Pervaiz, S. Resveratrol--from the bottle to the bedside? Leuk.Lymphoma 2001;40(5-6):491-498. View abstract.
  279. Soleas, G. J., Yan, J., and Goldberg, D. M. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr.B Biomed.Sci.Appl. 6-5-2001;757:161-172. View abstract.
  280. Dorrie, J., Gerauer, H., Wachter, Y., and Zunino, S. J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 6-15-2001;61:4731-4739. View abstract.
  281. Ahmad, N., Adhami, V. M., Afaq, F., Feyes, D. K., and Mukhtar, H. Resveratrol causes WAF-1/p21-mediated G-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin.Cancer Res. 2001;7:1466-1473. View abstract.
  282. Nakagawa, H., Kiyozuka, Y., Uemura, Y., Senzaki, H., Shikata, N., Hioki, K., and Tsubura, A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J.Cancer Res.Clin.Oncol. 2001;127:258-264. View abstract.
  283. Zhou, C. X., Kong, L. D., Ye, W. C., Cheng, C. H., and Tan, R. X. Inhibition of xanthine and monoamine oxidases by stilbenoids from Veratrum taliense. Planta Med 2001;67:158-161. View abstract.
  284. Shirataki, Y., Motohashi, N., Tani, S., Sakagami, H., Satoh, K., Nakashima, H., Mahapatra, S. K., Ganguly, K., Dastidar, S. G., and Chakrabarty, A. N. In vitro biological activity of prenylflavanones. Anticancer Res 2001;21(1A):275-280. View abstract.
  285. Chang, T. K. and Yeung, R. K. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can.J.Physiol Pharmacol. 2001;79:220-226. View abstract.
  286. Mollerup, S., Ovrebo, S., and Haugen, A. Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int.J.Cancer 4-1-2001;92:18-25. View abstract.
  287. Nicolini, G., Rigolio, R., Miloso, M., Bertelli, A. A., and Tredici, G. Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci.Lett. 4-13-2001;302:41-44. View abstract.
  288. Jonsson, K. O., Hedin, H. L., and Fowler, C. J. Investigation into the rapid effects of 17 beta-estradiol and neuroactive steroids upon beta-amyloid(25-35)-induced activation of phosphoinositide-specific phospholipase C in human platelets. Methods Find.Exp.Clin.Pharmacol 2000;22:615-620. View abstract.
  289. Giovannini, L., Migliori, M., Longoni, B. M., Das, D. K., Bertelli, A. A., Panichi, V., Filippi, C., and Bertelli, A. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc.Pharmacol. 2001;37:262-270. View abstract.
  290. Dong, Z. Effects of food factors on signal transduction pathways. Biofactors 2000;12(1-4):17-28. View abstract.
  291. Hadi, S. M., Asad, S. F., Singh, S., and Ahmad, A. Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB.Life 2000;50:167-171. View abstract.
  292. Kampa, M., Hatzoglou, A., Notas, G., Damianaki, A., Bakogeorgou, E., Gemetzi, C., Kouroumalis, E., Martin, P. M., and Castanas, E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr.Cancer 2000;37:223-233. View abstract.
  293. Chan, W. K. and Delucchi, A. B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 11-10-2000;67:3103-3112. View abstract.
  294. Heredia, A., Davis, C., and Redfield, R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J.Acquir.Immune.Defic.Syndr. 11-1-2000;25:246-255. View abstract.
  295. Wang, M. J., Huang, H. M., Hsieh, S. J., Jeng, K. C., and Kuo, J. S. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol. 1-1-2001;112(1-2):28-34. View abstract.
  296. Ahn, K. S., Kim, J. H., Oh, S. R., Ryu, S. Y., and Lee, H. K. Inhibitory activity of stilbenes from medicinal plants on the expression of cell adhesion molecules on THP1 cells. Planta Med. 2000;66:641-644. View abstract.
  297. Chang, T. K., Lee, W. B., and Ko, H. H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can.J.Physiol Pharmacol. 2000;78:874-881. View abstract.
  298. De, Santi C., Pietrabissa, A., Spisni, R., Mosca, F., and Pacifici, G. M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000;30:857-866. View abstract.
  299. Burkitt, M. J. and Duncan, J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch.Biochem.Biophys. 9-15-2000;381:253-263. View abstract.
  300. Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51:513-520. View abstract.
  301. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., and Klinge, C. M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000;141:3657-3667. View abstract.
  302. Stewart, J. R., Christman, K. L., and O'Brian, C. A. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem.Pharmacol. 11-1-2000;60:1355-1359. View abstract.
  303. Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26:144-150. View abstract.
  304. Bagchi, D., Bagchi, M., Stohs, S. J., Das, D. K., Ray, S. D., Kuszynski, C. A., Joshi, S. S., and Pruess, H. G. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 8-7-2000;148(2-3):187-197. View abstract.
  305. Schneider, Y., Vincent, F., Duranton, B., Badolo, L., Gosse, F., Bergmann, C., Seiler, N., and Raul, F. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 9-29-2000;158:85-91. View abstract.
  306. Bradamante, S., Piccinini, F., Barenghi, L., Bertelli, A. A., De Jonge, R., Beemster, P., and De Jong, J. W. Does resveratrol induce pharmacological preconditioning? Int.J Tissue React. 2000;22:1-4. View abstract.
  307. Szende, B., Tyihak, E., and Kiraly-Veghely, Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp.Mol.Med. 6-30-2000;32:88-92. View abstract.
  308. Andlauer, W., Kolb, J., Siebert, K., and Furst, P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp.Clin.Res 2000;26:47-55. View abstract.
  309. Delmas, D., Jannin, B., Cherkaoui, Malki M., and Latruffe, N. Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol.Rep. 2000;7:847-852. View abstract.
  310. Mietus-Snyder, M., Gowri, M. S., and Pitas, R. E. Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol.Chem 6-9-2000;275:17661-17670. View abstract.
  311. Mutoh, M., Takahashi, M., Fukuda, K., Matsushima-Hibiya, Y., Mutoh, H., Sugimura, T., and Wakabayashi, K. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 2000;21:959-963. View abstract.
  312. Naderali, E. K., Doyle, P. J., and Williams, G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci (Lond) 2000;98:537-543. View abstract.
  313. Ballmer, P. E. [The Mediterranean diet--healthy but and still delicious]. Ther.Umsch. 2000;57:167-172. View abstract.
  314. Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., Kelly, J. W., and Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct.Biol. 2000;7:312-321. View abstract.
  315. Martinez, J. and Moreno, J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem.Pharmacol 4-1-2000;59:865-870. View abstract.
  316. Subbaramaiah, K., Michaluart, P., Chung, W. J., Tanabe, T., Telang, N., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann.N.Y.Acad.Sci. 1999;889:214-223. View abstract.
  317. Mitchell, S. H., Zhu, W., and Young, C. Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 12-1-1999;59:5892-5895. View abstract.
  318. Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128:149-157. View abstract.
  319. Casper, R. F., Quesne, M., Rogers, I. M., Shirota, T., Jolivet, A., Milgrom, E., and Savouret, J. F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol.Pharmacol. 1999;56:784-790. View abstract.
  320. Ciolino, H. P. and Yeh, G. C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol.Pharmacol. 1999;56:760-767. View abstract.
  321. Lin, J. K. and Tsai, S. H. Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc.Natl.Sci.Counc.Repub.China B 1999;23:99-106. View abstract.
  322. Zou, J. G., Huang, Y. Z., Chen, Q., Wei, E. H., Hsieh, T. C., and Wu, J. M. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochem.Mol.Biol.Int. 1999;47:1089-1096. View abstract.
  323. Calabrese, G. Nonalcoholic compounds of wine: the phytoestrogen resveratrol and moderate red wine consumption during menopause. Drugs Exp.Clin.Res 1999;25(2-3):111-114. View abstract.
  324. Palmieri, L., Mameli, M., and Ronca, G. Effect of resveratrol and some other natural compounds on tyrosine kinase activity and on cytolysis. Drugs Exp.Clin.Res. 1999;25(2-3):79-85. View abstract.
  325. Hsieh, T. C. and Wu, J. M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp.Cell Res. 5-25-1999;249:109-115. View abstract.
  326. Miloso, M., Bertelli, A. A., Nicolini, G., and Tredici, G. Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci.Lett. 4-2-1999;264(1-3):141-144. View abstract.
  327. Jang, D. S., Kang, B. S., Ryu, S. Y., Chang, I. M., Min, K. R., and Kim, Y. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem.Pharmacol. 3-15-1999;57:705-712. View abstract.
  328. Rahman, I. Antioxidant therapeutic advances in COPD. Ther.Adv.Respir.Dis. 2008;2:351-374. View abstract.
  329. Kimura, Y., Okuda, H., and Kubo, M. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J Ethnopharmacol. 1995;45:131-139. View abstract.
  330. Banerjee, S., Bueso-Ramos, C., and Aggarwal, B. B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 9-1-2002;62:4945-4954. View abstract.
  331. Manna, S. K., Mukhopadhyay, A., and Aggarwal, B. B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 6-15-2000;164:6509-6519. View abstract.
  332. Bakker, G. C., van Erk, M. J., Pellis, L., Wopereis, S., Rubingh, C. M., Cnubben, N. H., Kooistra, T., van, Ommen B., and Hendriks, H. F. An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am.J Clin Nutr. 2010;91:1044-1059. View abstract.
  333. Rotches-Ribalta, M., Andres-Lacueva, C., Estruch, R., Escribano, E., and Urpi-Sarda, M. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res 2012;66:375-382. View abstract.
  334. De, Groote D., Van, Belleghem K., Deviere, J., Van, Brussel W., Mukaneza, A., and Amininejad, L. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Ann Nutr Metab 2012;61:15-24. View abstract.
  335. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F. J., Aviles-Plaza, F., Parra, S., Yanez-Gascon, M. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol.Nutr Food Res 2012;56:810-821. View abstract.
  336. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., Garcia-Almagro, F. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 8-1-2012;110:356-363. View abstract.
  337. Kamiyama, M., Kishimoto, Y., Tani, M., Andoh, K., Utsunomiya, K., and Kondo, K. Inhibition of low-density lipoprotein oxidation by Nagano purple grape (Vitis viniferaxVitis labrusca). J Nutr.Sci.Vitaminol.(Tokyo) 2009;55:471-478. View abstract.
  338. Leifert, W. R. and Abeywardena, M. Y. Cardioprotective actions of grape polyphenols. Nutr.Res 2008;28:729-737. View abstract.
  339. Lekakis, J., Rallidis, L. S., Andreadou, I., Vamvakou, G., Kazantzoglou, G., Magiatis, P., Skaltsounis, A. L., and Kremastinos, D. T. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur.J Cardiovasc.Prev.Rehabil. 2005;12:596-600. View abstract.
  340. Zern, T. L., Wood, R. J., Greene, C., West, K. L., Liu, Y., Aggarwal, D., Shachter, N. S., and Fernandez, M. L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;135:1911-1917. View abstract.
  341. Larrosa, M., Tomas-Barberan, F. A., and Espin, J. C. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric.Food Chem 7-30-2003;51:4576-4584. View abstract.
  342. Piver, B., Berthou, F., Dreano, Y., and Lucas, D. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci. 7-18-2003;73:1199-1213. View abstract.
  343. Khanna, S., Venojarvi, M., Roy, S., Sharma, N., Trikha, P., Bagchi, D., Bagchi, M., and Sen, C. K. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic.Biol.Med 10-15-2002;33:1089-1096. View abstract.
  344. Bhat, K. P. L., Kosmeder, J. W., and Pezzuto, J. M. Biological effects of resveratrol. Antioxid.Redox.Signal. 2001;3:1041-1064. View abstract.
  345. Khanna, S., Roy, S., Bagchi, D., Bagchi, M., and Sen, C. K. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic.Biol.Med 7-1-2001;31:38-42. View abstract.
  346. de, Santi C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000;30:1047-1054. View abstract.
  347. Hsieh, T. C. and Wu, J. M. Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 2000;20(1A):225-228. View abstract.
  348. Mozaffarieh, M., Grieshaber, M. C., Orgul, S., and Flammer, J. The potential value of natural antioxidative treatment in glaucoma. Surv.Ophthalmol. 2008;53:479-505. View abstract.
  349. Karlsen, A., Paur, I., Bohn, S. K., Sakhi, A. K., Borge, G. I., Serafini, M., Erlund, I., Laake, P., Tonstad, S., and Blomhoff, R. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur.J.Nutr. 2010;49:345-355. View abstract.
  350. Rosa, F. T., Zulet, M. A., Marchini, J. S., and Martinez, J. A. Bioactive compounds with effects on inflammation markers in humans. Int J Food Sci Nutr 2012;63:749-765. View abstract.
  351. Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299:874-882. View abstract.
  352. Basly, J. P., Marre-Fournier, F., Le Bail, J. C., Habrioux, G., and Chulia, A. J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 1-21-2000;66:769-777. View abstract.
  353. Mueller SO, Simon S, Chae K, et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25. View abstract.
  354. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-52. View abstract.
  355. Lyons MM, Yu C, Toma RB, et al. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 2003;51:5867-70. View abstract.
  356. Trincheri NF, Nicotra G, Follo C, et al. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 2007;28:922-31. View abstract.
  357. Scarlatti F, Sala G, Somenzi G, et al. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003;17:2339-41. View abstract.
  358. Wang Q, Li H, Wang XW, et al. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 2003;351:83-6. View abstract.
  359. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:942-6. View abstract.
  360. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-85. View abstract.
  361. Savaskan E, Olivieri G, Meier F, et al. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003;49:380-3. View abstract.
  362. Gao X, Deeb D, Media J, et al. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 2003;66:2427-35. View abstract.
  363. Schriever C, Pendland SL, Mahady GB. Red wine, resveratrol, Chlamydia pneumoniae and the French connection. Atherosclerosis 2003;171:379-80. View abstract.
  364. Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 2004;134:5-10. View abstract.
  365. Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 2004;11:441-6. View abstract.
  366. Zhang Y, Jayaprakasam B, Seeram NP, et al. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004;52:228-33. View abstract.
  367. Opipari AW Jr, Tan L, Boitano AE, et al. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004;64:696-703. View abstract.
  368. Abou-Zeid LA, El-Mowafy AM. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding. Chirality 2004;16:190-5. View abstract.
  369. Meng X, Maliakal P, Lu H, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004;52:935-42. View abstract.
  370. Hascalik S, Celik O, Turkoz Y, et al. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol Obstet Invest 2004;57:218-23. View abstract.
  371. Ahmad KA, Clement MV, Hanif IM, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 2004;64:1452-9. View abstract.
  372. Li W, Seifert M, Xu Y, Hock B. Comparative study of estrogenic potencies of estradiol, tamoxifen, bisphenol-A and resveratrol with two in vitro bioassays. Environ Int 2004;30:329-35. View abstract.
  373. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-410. View abstract.
  374. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004;279:22727-37. View abstract.
  375. Wang Z, Huang Y, Zou J, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002;9:77-9. View abstract.
  376. Mokni M, Limam F, Elkahoui S, et al. Strong cardioprotective effect of resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch Biochem Biophys 2007;457:1-6. View abstract.
  377. Elmali N, Baysal O, Harma A, et al. Effects of resveratrol in inflammatory arthritis. Inflammation 2007;30:1-6. View abstract.
  378. Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006;6:35. View abstract.
  379. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42. View abstract.
  380. Zhou S, Koh HL, Gao Y, et al. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004;74:935-68. View abstract.
  381. Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004;12:5571-8. View abstract.
  382. Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.
  383. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58. View abstract.
  384. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36:79-87.. View abstract.
  385. Docherty JJ, Fu MM, Stiffler BS, et al. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999;43:145-55. View abstract.
  386. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000;141:3657-67.
  387. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. View abstract.
  388. Laden BP, Porter TD. Resveratrol inhibits human squalene monooxygenase. Nutr Res 2001;21:747-53.
  389. Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action.Cancer Lett 2001;167:151-6. View abstract.
  390. Schneider Y, Vincent F, Duranton B, et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000;158:85-91.
  391. Holmes-McNary M, Baldwin AS, Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000;60:3477-83. View abstract.
  392. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3. View abstract.
  393. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997;94:14138-43. View abstract.
  394. Carbo N, Costelli P, Baccino FM, et al. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999;254:739-43. View abstract.
  395. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42. View abstract.
  396. Davy BM, Melby CL, Beske SD, et al. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr 2002;132:394-8.. View abstract.
  397. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996;27:363-6. View abstract.
  398. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8. View abstract.
  399. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19. View abstract.
  400. Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3. View abstract.
  401. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. View abstract.
  402. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20. View abstract.
  403. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113. View abstract.
  404. Agri Res Svc: Dr. Duke's phytochemical and ethnobotanical databases. www.ars-grin.gov/duke (Accessed 3 November 1999).
  405. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  406. Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
  407. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  408. Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
  409. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  410. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Documento revisado - 08/26/2015